Interventional radiology

ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, March 28, 2023
Injection, Taiwan, Society, Kidney failure, Chronic kidney disease, D, Safety, PIPE, Society of Interventional Radiology, European Medicines Agency, REACT, SIR, Marketing, Interventional radiology, Journal, Patient, Physician, Kidney, Medicines and Healthcare products Regulatory Agency, Research, FDA, Health Canada, CKD, BLA, SVP, Food, SCS, Pharmaceutical industry, Cryptocurrency, EU

WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the fourth quarter ended December 31, 2022, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the fourth quarter ended December 31, 2022, and provided an update on recent corporate developments.
  • We remain actively engaged with the FDA, facilitated by REACT’s RMAT designation, to ensure that the steps we are taking today are positioning REACT for future success.
  • The Company currently has protocol allowances in Belgium, France, Singapore, Spain and Austria, with additional country-specific allowances pending.
  • Cash Position: Cash and cash equivalents as of December 31, 2022, were $490.3 million, compared to $20.6 million on December 31, 2021.

Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases

Retrieved on: 
Thursday, March 23, 2023
Well, Galway Clinic, SAB, IVC, KOL, Galway, Cardiovascular and Interventional Radiological Society of Europe, Society, Center of excellence, Intervention, Vision-guided robot systems, Consultant, Society of Interventional Radiology, Radiology, DVT, CIRSE, Prostate, Vein, SIR, Professor, Interventional radiology, Publication, Executive Committee, Clinical, SPC, European Board of Ophthalmology, Medical imaging

HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from interventional radiologists due to the gap in new innovative technology currently available on the market today. Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB). The Company believes the combination of his academic and medical experience will be invaluable while it seeks to establish Centers of Excellence throughout the U.S. and Europe in preparation for human clinical trials.

Key Points: 
  • Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB).
  • Annually, Professor O’Sullivan performs large volumes of prostate and uterine fibroid embolizations, as well as the full array of Interventional procedures.
  • “I believe interventional radiologists have been seeking a better solution to address their concerns, while still achieving favorable patient outcomes.
  • For a complete list and background on the members of the SAB, please visit the Company’s website at www.microbotmedical.com .

NRMP® Celebrates Match Day by Publishing the Results of a Record-Breaking 2023 Main Residency Match®

Retrieved on: 
Friday, March 17, 2023
Acceptance, Emergency medicine, Pediatrics, Obstetrics, Anesthesiology, Face, Obstetrics and gynaecology, Radiology, MBA, History, Competition (economics), BSN, Family medicine, Cardiothoracic surgery, Child, DO, National Resident Matching Program, Interventional radiology, NRMP, MD, Patient, Physician, Pathology, Doctor of Health Science, Internal medicine, Vascular surgery, Physical medicine and rehabilitation, Otorhinolaryngology, Neurology, IMG, Anne Ferguson-Smith, Internship, Integration, Orthopedic surgery, Developmental Medicine & Child Neurology, Nursing, Health insurance, Dentistry, SOAP, Psychiatry, Match, Gynaecology, Surgery

WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.

Key Points: 
  • WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.
  • "The 2023 Main Residency Match proved once again to be a highly successful Match with outstanding results for participants.
  • There were 48,156 total applicants registered in the 2023 Main Residency Match, an increase of 481 applicants over last year.
  • SOAP results will be available in the 2023 Main Residency Match Results and Data Book, which is published in the Spring.

Microbot Medical Launches Presence in the United Kingdom as Highly Accomplished Consultant Interventional Radiologist Professor Mark W. Little Joins its Scientific Advisory Board as Efforts to Commercialize the LIBERTY® Robotic System Continue to Acceler

Retrieved on: 
Thursday, March 16, 2023
Research, United Kingdom, Oxford, Interventional radiology, Center for Radiological Research, FHEA, Medicine, Prostate, Failure, Prostatic artery embolization, CVIR, Bachelor of Science, Circulatory system, Master of Science, GAE, FRCR, Clinical Radiology, Royal Berkshire NHS Foundation Trust, Area studies, MBBS, CCT, SAB, ACF, NIHR, Princeton University Department of Psychology, United States Air Force Scientific Advisory Board, National Institute for Health and Care Research, Medical imaging

Professor Little is expected to work with other esteemed SAB members to advance the regulatory and commercialization plans for the LIBERTY Robotic System, the first single-use endovascular robotic system.

Key Points: 
  • Professor Little is expected to work with other esteemed SAB members to advance the regulatory and commercialization plans for the LIBERTY Robotic System, the first single-use endovascular robotic system.
  • Professor Little is Consultant Interventional Radiologist & Radiology Research Lead working in Berkshire and London.
  • “I recently participated in a study for the LIBERTY Robotic System, along with several other leading clinicians.
  • He is a current specialist advisor on NICE’s Interventional Procedures Program and is on the editorial board for CVIR.

Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board

Retrieved on: 
Monday, March 13, 2023
Associate, Research, International Congress of Radiology, Doctor of Philosophy, Fair Employment Practice Committee, SAB, Dialysis, Radiology, KOL, Moyamoya disease, Committee, MD, IEEE SA International Award, American College, EU, Hospital, Titles of distinction awarded by the University of Oxford, Editorial board, Journal, European Board of Ophthalmology, Growth, Collection, Editor-in-chief, Interventional oncology, PubMed, Interventional radiology, Journal of Intelligent and Robotic Systems, Circulatory system, CIRSE, Medical imaging, Nursing

“I was quite impressed when I first used the LIBERTY® Robotic System, and I immediately recognized the significant clinical impact and needed to get involved,” commented Dr. Spiliopoulos.

Key Points: 
  • “I was quite impressed when I first used the LIBERTY® Robotic System, and I immediately recognized the significant clinical impact and needed to get involved,” commented Dr. Spiliopoulos.
  • “The addition of Dr. Spiliopoulos, the first member from Greece, reaffirms our commitment to recruit sought-after and well-published interventional radiologists across Europe and the Americas.
  • Dr. Spiliopoulos has published more than 200 peer-reviewed PubMed articles (more than 3.500 citations in Scopus) and 19 book chapters.
  • For a complete list and background on the members of the SAB, please visit www.microbotmedical.com .

Mid-Atlantic Permanente Medical Group Selects Medality to Support Radiologists Professional Education and Development

Retrieved on: 
Tuesday, March 14, 2023
Online, McLean, Gorgas Medal, American Board of Radiology, Accreditation, Entrepreneurship, Education, Educational technology, Diagnosis, American Board of Commissioners for Foreign Missions, Learning, Continuing medical education, MOC, Culture, AMA, Accreditation Council, MD, Accreditation Council for Continuing Medical Education, National Association Medical Staff Services, Kaiser Permanente, SCCT, Health, Interventional radiology, ACCME, Partnership, Medical imaging, Radiology

CINCINNATI, March 14, 2023 /PRNewswire-PRWeb/ -- Today, Mid-Atlantic Permanente Medical Group (MAPMG), one of the nation's premier multi-specialty medical groups, announced that it has selected Medality, formerly MRI Online, as its radiology practice development platform of choice.

Key Points: 
  • Mid-Atlantic Permanente Medical Group partners with Medality to upskill radiologists in advanced imaging areas.
  • CINCINNATI, March 14, 2023 /PRNewswire-PRWeb/ -- Today, Mid-Atlantic Permanente Medical Group (MAPMG), one of the nation's premier multi-specialty medical groups, announced that it has selected Medality, formerly MRI Online, as its radiology practice development platform of choice.
  • The partnership with Medality demonstrates MAPMG's dedication to investing in the ongoing education and development of its radiologists and its commitment to excellence in patient care.
  • "Partnering with Medality provides our team with the opportunity to leverage a nimble and digital educational platform for high caliber professional education and development, meeting our radiologists right where they are," said Ainsley MacLean, MD, Chief Medical Information Officer & Associate Medical Director for Diagnostic and Interventional Radiology, Mid-Atlantic Permanente Medical Group.

Argon Medical Devices Modernizes Portal Vein Access with the Launch of the TRAVELER™ Series

Retrieved on: 
Tuesday, March 7, 2023
Senior, Interventional, Physician, Interventional radiology, Incidence, Cirrhosis, Argon, Transjugular intrahepatic portosystemic shunt, Patient, Vascular surgery, University, Global marketing, Caregiver, TIPS, Portal vein, Interventional cardiology, Anatomy, Liver, Medical imaging, Oncology

PLANO, Texas, March 7, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, introduces the TRAVELER™ Portal Vein Access Series as the newest addition to its portal vein access product portfolio.

Key Points: 
  • PLANO, Texas, March 7, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, introduces the TRAVELER™ Portal Vein Access Series as the newest addition to its portal vein access product portfolio.
  • The product line is designed to meet the challenging needs of physicians accessing the portal vein through the liver during Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.
  • "Several innovative features of the TRAVELER set make it easier to access the portal vein compared to other sets on the market.
  • Thus, we were compelled to act when we identified an opportunity to simplify complex portal vein access procedures for our customers.

New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors

Retrieved on: 
Tuesday, March 7, 2023
Pleural cavity, Radiofrequency ablation, Lung cancer, Neoplasm, Mouse, Therapy, Patient, RFA, NSCLC, Food, Society, Immune system, Investment, Immunotherapy, SIR, PEF, Food and Drug Administration, Society of Interventional Radiology, Safety, Interventional radiology, Galvanization, Trial of the century, Food preservation, Medical imaging, PHOENIX

PHOENIX, March 7, 2023 /PRNewswire/ -- New interventional oncology data from Galvanize Therapeutics demonstrate positive pre-clinical and early clinical study results using the Aliya™ Pulsed Electric Field (PEF) system.

Key Points: 
  • PEF treatment significantly reduced malignant tissue, and 95% of the assessed sensitive structures within the PEF treatment zone remained viable and unaffected by the PEF energy.
  • Additionally, PEF increased tertiary lymphoid structure accumulation, indicating potential immunoactivation with PEF.
  • PEF also showed greater suppression of tumor growth and had a synergistic effect in combination with immunotherapy, unlike RFA.
  • "We are making additional investments to expand our Aliya™ clinical research program, including a U.S. clinical study of patients with NSCLC."

SIR Foundation Receives Major Gift to Support Research Grants and Panel on Uterine Health

Retrieved on: 
Monday, March 6, 2023
MD, Physician, Society of Interventional Radiology, Uterine fibroid, UFE, Adenomyosis, Research, Uterine artery embolization, Woman, Patient, Collection, Society, SIR, Knowledge, Interventional radiology, Pharmaceutical industry, Medical device

PHOENIX, March 6, 2023 /PRNewswire/ -- The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward.

Key Points: 
  • PHOENIX, March 6, 2023 /PRNewswire/ -- The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward.
  • The announcement was made at the SIR Foundation Gala on March 5 during the SIR 2023 Annual Scientific Meeting.
  • The Dr. Scott C. Goodwin Uterine Artery Embolization Grant is focused on advancing uterine fibroid and uterine artery embolization research and will launch in October 2023.
  • Spies, MD, FSIR, are highly regarded pioneers of uterine fibroid research, having led the SIR Foundation's Fibroid Registry, the largest collection of data on uterine fibroids, and conducted foundational research into uterine artery embolization.

Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial

Retrieved on: 
Saturday, March 4, 2023
Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Practice Management, Biotechnology, Biometrics, Health, Pulmonary embolism, National Heart, Lung, and Blood Institute, Patient, Viz, AI, Faculty, Clinical trial, Workflow, Anticoagulant, Lung, Thrombolysis, Interventional radiology, Weill Cornell Medicine, Bangladesh Technical Education Board, Research, Triage, Medical imaging, Pharmaceutical industry

The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.

Key Points: 
  • The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
  • Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
    Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates.
  • “We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT.
  • With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai.